



September 6, 2024

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

**“Strides receive USFDA approval for
Theophylline Extended-Release Tablets, 300 mg and 450 mg”**

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg

- *Strides is the “first approved applicant” and is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity for Theophylline Extended-Release Tablets, 300 mg*

Bangalore, India, September 6, 2024 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic version of Theophylline Extended-Release Tablets, 300 mg and 450 mg, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR[®], of Schering Corp. Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of ~US\$ 11.5 mn, with the 300 mg dosage contributing ~US\$ 10.8 mn as per IQVIA. The Theophylline Extended-Release Tablets, 300 mg and 450 mg will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.

About Theophylline

Theophylline Extended-Release Tablets (300 mg and 450 mg) are used to manage respiratory conditions like chronic asthma, chronic obstructive pulmonary disease (COPD), and bronchospasm. The medication works as a bronchodilator, relaxing the muscles around the bronchial tubes to ease breathing. It is particularly helpful in preventing and treating symptoms such as wheezing, shortness of breath, and chest tightness. The extended-release formulation allows for prolonged drug release, reducing the frequency of dosing and providing consistent relief from symptoms over time.

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Institutional Investors

Vikesh Kumar

Group CFO

investor-relations@strides.com

Saurabh Ambaselkar

Investor Relations

+91 99609 31220

saurabh.ambaselkar@strides.com

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Office: Strides House, Bannerghatta Road,
Bengaluru – 560076

Corporate Communication

Pallavi Panchmatia: +91 80 6784 0193

Pallavi.panchmatia@strides.com

PR Consultancy

Adfactors PR

Janhavi Bellare: +91 93228 54508

Janhavi.bellare@adfactorspr.com

Talal Syed: +91 99876 19679

syed.talal@adfactorspr.com